The aims of the study were not only to clarify LATS2 mRNA and protein expression in CRC patients by quantitative real-time PCR (qRT-PCR) and tissue microarray (TMA) immunohistochemistry analyses, respectively, but also to determine the correlations of LATS2 with clinicopathological characteristics and evaluate its prognostic role in these patients. The gene discussed is LATS2; the disease is colorectal carcinoma.